Generation Bio to Present at the JMP Securities Life Sciences Conference

Rhea-AI Summary

Generation Bio Co. (Nasdaq: GBIO) announced that CEO Geoff McDonough will present at the JMP Securities Life Sciences Conference on June 16 at 11:30 a.m. ET. A live webcast of the presentation will be available on the company's investor website, with a replay available for 30 days. The company specializes in non-viral gene therapies aimed at providing durable treatments for various diseases, utilizing a unique platform that combines high-capacity DNA constructs and targeted delivery systems. Generation Bio is committed to broadening access to gene therapy worldwide.

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the JMP Securities Life Sciences Conference on Wednesday, June 16, at 11:30 a.m. ET.

A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio

Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.

For more information, please visit www.generationbio.com.

Contact:

Investors 
Maren Killackey
Generation Bio
mkillackey@generationbio.com
541-646-2420

Media 
Alicia Webb
Generation Bio
awebb@generationbio.com
847-254-4275

Stephanie Simon 
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

FAQ

When will Generation Bio present at the JMP Securities Life Sciences Conference?

Generation Bio will present on June 16, 2021, at 11:30 a.m. ET.

How can I watch the Generation Bio presentation at the JMP Securities Life Sciences Conference?

You can watch the presentation live via webcast on Generation Bio's investor website.

What is the focus of Generation Bio's gene therapy platform?

Generation Bio's platform focuses on creating non-viral gene therapies for durable, redosable treatments for various diseases.

What technologies does Generation Bio use for gene therapy?

Generation Bio utilizes closed-ended DNA constructs and cell-targeted lipid nanoparticle delivery systems in its therapies.

What is the stock symbol for Generation Bio?

The stock symbol for Generation Bio is GBIO.

How long will the webcast replay be available after the conference?

The replay of the webcast will be available for 30 days following the event.